title: [Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
abstract: 35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF). We observed nor or a little bit ascites in 87.5 per cent after TNF and in 66.5 per cent after mitoxantrone. In addition we applied a systemic monochemotherapy. After mitomycin C or interferon beta only in 40 per cent each an effect could be observed. TNF to day is the most effective substance for treating ascites with moderate toxicity.
authors.affiliation: Universitäts-Frauenklinik Bonn.
authors.forename: A
authors.initials: A
authors.lastname: Werner
authors.forename: P
authors.initials: P
authors.lastname: Mallmann
authors.forename: A
authors.initials: A
authors.lastname: Chronides
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
authors.forename: U
authors.initials: U
authors.lastname: Wagner
authors.forename: D
authors.initials: D
authors.lastname: Krebs
mesh_terms: D001201:Ascites / Q000628:therapy*; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage*; D016685:Mitomycin / Q000008:administration & dosage*; D008942:Mitoxantrone / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*; D014594:Uterine Neoplasms / Q000628:therapy*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D016685:Mitomycin; D016899:Interferon-beta; D008942:Mitoxantrone
vernacular_title: Lokoregionale Ascitestherapie mit Zytostatika und Immunmodulatoren bei gynäkologischen Malignomen.